Companies Dominating the Prednisone Market
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Merck & Co., Inc.
- GSK plc
- Sanofi
- AstraZeneca
- Eli Lilly and Company
- AbbVie Inc.
- Bristol Myers Squibb Company
- F. Hoffmann-La Roche Ltd
- Teva Pharmaceutical Industries Ltd.
Browse Key Market Insights with Data Illustration:
In the News
- October 5, 2023: Pfizer Inc. declared that ABRILADA, an interchangeable biosimilar of Humira (adalimumab), has been approved by the U.S. Food and Drug Administration (FDA). All approved uses of ABRILADA are covered by the interchangeable designation, which also includes some patients with psoriatic arthritis, juvenile idiopathic arthritis, rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.
- March 2, 2023: An ODAC meeting will be held by the U.S. Food and Drug Administration (FDA) to discuss the supplemental new drug application (sNDA) for LYNPARZA, which is intended to be used in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer. AstraZeneca and Merck & Co., Inc., which are referred to as MSD outside of the United States and Canada, made this announcement. On marketed and experimental medications for use in cancer treatment, the ODAC offers the FDA unbiased, professional opinions and recommendations. Although the committee's recommendations are not legally binding, the FDA does take them into account.
